Actuate Therapeutics Receives Nasdaq Minimum Bid-Price Deficiency Notice

Nasdaq notified Actuate Therapeutics that its stock closed below the $1.00 minimum bid price for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has until April 26, 2027, to regain compliance; the notice has no immediate effect on trading.